Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who respond to poly(ADP-ribose) polymerase inhibitor (PARPi) therapy is of great clinical importance. Here we show that quantitative BRCA1 methylation analysis provides new insight into PARPi response in preclinical mod...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Kondrashova, Olga, Topp, Monique, Nesic, Ksenija, Lieschke, Elizabeth, Ho, Gwo-Yaw, Harrell, Maria I., Zapparoli, Giada V., Hadley, Alison, Holian, Robert, Boehm, Emma, Heong, Valerie, Sanij, Elaine, Pearson, Richard B., Krais, John J., Johnson, Neil, McNally, Orla, Ananda, Sumitra, Alsop, Kathryn, Hutt, Karla J., Kaufmann, Scott H., Lin, Kevin K., Harding, Thomas C., Traficante, Nadia, deFazio, Anna, McNeish, Iain A., Bowtell, David D., Swisher, Elizabeth M., Dobrovic, Alexander, Wakefield, Matthew J., Scott, Clare L.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6162272/
https://ncbi.nlm.nih.gov/pubmed/30266954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-05564-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars